Dr Rosenberg

Dr. Mark Rosenberg received his undergraduate degree from the University of Pennsylvania and his medical degree from Georgetown University School of Medicine in 1988. Dr. Rosenberg completed his residency in emergency medicine where he was awarded “Resident and Teacher of the Year.” Dr. Rosenberg has been director/assistant director of several emergency departments, including Walter Reed Army Medical Center.

While staying active in academic emergency medicine, Dr. Rosenberg began contemplating methods to improve healthcare, such as how to improve treatment of the cause of medical disorders, rather than just treating the symptoms. In the late 1990s, Dr. Rosenberg reviewed the literature regarding obesity drugs and subsequently developed a novel drug for the treatment of obesity, for which he filed a patent.

Dr. Rosenberg’s drug development for obesity was sidetracked, when his mother presented to his emergency department with chest pain. Dr. Rosenberg diagnosed his mother with non-small cell lung cancer, that had metastasized to the liver, spleen, and bilateral adrenal glands. Dr. Rosenberg consulted with oncologists at preeminent cancer centers, where he learned the following: for most solid cancers (as opposed to leukemias and lymphomas), we have extended survival by approximately 2 months over the past 20 years.

Dr. Rosenberg’s career path swiftly and abruptly changed course, toward the study of cancer. He began studying tumor metabolism and then became the program director for the first Integrative Cancer Fellowship in the U.S.

Dr. Rosenberg and his team began working with Univ. of Minnesota, and eventually filed patents, on novel monocarboxylate transport inhibitors (MCT). MCTs are responsible for transporting lactic acid outside and inside the cancer cell, which are transporters that are vital for progression of many cancers.

Simultaneous with the work on MCTs, Dr. Rosenberg began looking at the literature regarding drugs that target cancer stem cells (CSC). CSCs, which are resistant to most cancer treatments (including chemotherapy), are the primary reason for cancer treatment failure. The literature revealed that salinomycin, an antibiotic that has been used in chicken and pig feed for over 30 years, exquisitely targets and kills CSC. Although exciting, there are two problems with this drug:

  • Neurotoxicity
  • Patent expired long ago, so there is no financial incentive to sponsor a clinical trial.

Dr. Rosenberg took 2 patients with end-stage small cell lung cancer and treated them outside of the U.S. with salinomycin, achieving complete remission in both cases. As of the time this article was written, the first patient has been in remission for 4.5 years and the second for 3.5 years.

Dr. Rosenberg and his team started a pharmaceutical company and partnered with a few individuals from Harvard, with the goal being to reduce toxicity of salinomycin, while improving its selectivity for cancer cells, thereby sparing normal cells. The animal studies look extremely promising, so Dr. Rosenberg merged his company with another pharmaceutical company, which will likely improve his ability to raise funds for the first human trial.

Dr. Rosenberg’s career path has clearly taken an unusual turn, but he has dedicated his life to making a difference in the lives of those effected by cancer.

Learn more about Dr. Mark Rosenberg, MD


  • July 1990 – July 1993 Emergency Medicine Residency Brooke Army Medical Center Dept. of Emergency Medicine San Antonio, TX
  • July 1988 – July 1989 Transitional Internship Fitzsimons Army Medical Center Aurora, CO
  • July 1984 – May 1988 Doctor of Medicine Georgetown University School of Medicine Washington, DC
  • July 1982 – June 1983 Master of Science in Physiology Georgetown University Graduate School Washington, DC
  • Sept 1978 – May 1982 Bachelor of Arts in Biology University of Pennsylvania Philadelphia, PA

Committees/Advisory Board

  • 2011 - Present; Medical Advisor to Life Length Telomere Analysis Technology
  • 2003 - 2005; Chairman of Pharmacy and Therapeutics Committee, Bethesda Memorial Hospital
  • 2003 - 2005; Institutional Review Board, Bethesda Memorial Hospital
  • 2003 - Present; Consultant to the National Strength and Conditioning Assoc.
  • 2000 - 2005; Emergency Department Committee, Bethesda Memorial Hospital
  • 1999 - Present; Medical Advisor to Fitness Institute International
  • 1990 - Present; American College of Emergency Physicians


  • 2009; Board Certified, American Academy of Anti-aging Medicine
  • 2001; Diplomate of the American Academy of Anti-aging Medicine
  • 1996; Fellow of the American College of Emergency Physicians
  • 1994; Board-Certified by the American Board of Emergency Medicine
  • 1989; Diplomate of the National Board of Medical Examiners
  • 1989-1999; ATLS Provider and Instructor, American College of Surgeons
  • 1990-1992; PALS Provider, American Academy of Pediatrics
  • 1988-Present; ACLS Provider, American Heart Association
  • 1998; Certified Hypnotherapist, National Guild of Hypnotists
  • 1998; Certified Personal Trainer, National Strength and Conditioning Assoc.


  • 1989; US Army Certificate of Achievement Award, for performance above and beyond the call of duty during the tornado disaster in Alabama
  • 1989; US Army Commendation Medal
  • 1993; Award for Outstanding Senior Resident and Teacher
  • 1999; Valedictorian and Distinguished Speaker, Fitness Institute International
  • 1999; Cover of the monthly journal, "The Florida Hypnotist"


  • Epstein A, Zhang D, Schultz J, Rosenberg M, Kupcha P, Stellar E: The Failure of Ventricular Sodium to Control Sodium Appetite in the Rat; Journal of Physiology and Behavior. 32:683-686, 1984
  • Rosenberg, Mark A: Toxndex, Toxicological Emergency Reference Manual; Delray Beach, FL, MQ INC, 1991

Research Experience

  • Patent Pending in the U.S., Canada, and the European Union - CCK based oral appetite suppressant for the treatment of obesity, filed February 23, 2007
  • Development of "Cancer Cocktail"; U.S. Application Serial No. 13/464,896
    Title: Cytotoxic Therapy By Proton Flux Modulation
    Date Filed: May 4, 2012
  • IND status granted Feb 24, 2007 for use of angiotensin II to
    improve tumor blood flow during administration of cytotoxic cancer therapy
  • 2007- Wake Forest University; Inhibition of tumor growth in mice through glycolytic inhibition
  • 2009 - University of Miami; Inhibition of cancer growth (in vitro) through inhibition of proton pump and monocarboxylate transporters

Professional Experience

  • 2012 – Present; Medical Director; AML Diagnostics
  • 2012 – Present; Board of Directors; American Academy of Anti-aging medicine
  • 2011 – Present; Medical Advisor to Life Length Telomere Analysis Technology
  • 2010 – 2012; Medical Director, Age Diagnostic Laboratories
  • 2009 – Present; Program Director; Integrative Cancer fellowship
  • 2008 – Present; Chief Medical Officer; Rose Pharmaceuticals
  • 2006 – Present; Chief Science Officer and Director of research and Development; Vitalmax Vitamins
  • 2003 – Present; President and Medical Director The Institute for Healthy Aging, Delray Beach, FL
  • 2003 – 2004; Chief Science Officer and Director of Research and Development, “Nutrophy”, Miami, FL
  • 1999 – 2005; Assistant Director of Emergency Medicine, Bethesda Memorial Hospital, Boynton Beach, FL
  • 1996 – 1999; Associate Director of Emergency Medicine and Director of Quality Improvement, Westside Regional Medical Center, Plantation, FL
  • 1993 – 1996; Assistant Chief of Emergency Medicine; Consultant for Poisons and Overdoses; Director of Quality Improvement Walter Reed Army Medical Center, Washington, DC
  • 1995 – 1996; Staff Emergency Physician, Shady Grove Adventist Hospital, Rockville, MD